Independent health-science reporting · Evidence ratedEvidence rated
Independent health-science reporting
Beyond today’s standard of care.
Every story carries an evidence rating, named sources, and a plain account of what remains uncertain.
A survey-based study shows higher odds of post-diagnosis cannabis use among cancer survivors reporting average or below average mental health.
A cross-sectional registry analysis shows a marked rise in trials initiated after 2016 and a significant increase in industry sponsorship.
An economic simulation shows that blood-based gastric cancer screening is too expensive for average-risk individuals.
A new feasibility study is evaluating how digitally supported physical exercise programs can be equitably implemented during and after cancer treatment.
Cancer Innovation
Treatment, resistance, and the science reshaping oncology.
10 stories
Precision Medicine
Matching treatment to biology, one patient at a time.
10 stories
Diagnostics
Detection, monitoring, and the limits of early testing.
2 stories
Integrative & Supportive Care
Tolerability, recovery, and quality of life during treatment.
7 stories
Research & Trials
What is being studied, where, and what it would prove.
6 stories
Announcements, paid press releases, and sponsored features. This material is not produced by the NSH editorial desk.
The agency approved the estrogen receptor antagonist for use in combination with a CDK4/6 inhibitor.
October 14, 2026
The agency approved the kinase inhibitor for adult patients with locally advanced or metastatic disease.
September 15, 2026
